Bristol Myers Squibb Total Assets 2010-2022 | BMY

Bristol Myers Squibb total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Bristol Myers Squibb total assets for the quarter ending September 30, 2022 were $98.196B, a 11.45% decline year-over-year.
  • Bristol Myers Squibb total assets for 2021 were $109.314B, a 7.74% decline from 2020.
  • Bristol Myers Squibb total assets for 2020 were $118.481B, a 8.82% decline from 2019.
  • Bristol Myers Squibb total assets for 2019 were $129.944B, a 271.42% increase from 2018.
Bristol Myers Squibb Annual Total Assets
(Millions of US $)
2021 $109,314
2020 $118,481
2019 $129,944
2018 $34,986
2017 $33,551
2016 $33,707
2015 $31,748
2014 $33,749
2013 $38,592
2012 $35,897
2011 $32,970
2010 $31,076
2009 $31,008
Bristol Myers Squibb Quarterly Total Assets
(Millions of US $)
2022-09-30 $98,196
2022-06-30 $100,357
2022-03-31 $103,034
2021-12-31 $109,314
2021-09-30 $110,893
2021-06-30 $110,797
2021-03-31 $112,435
2020-12-31 $118,481
2020-09-30 $125,536
2020-06-30 $128,076
2020-03-31 $129,285
2019-12-31 $129,944
2019-09-30 $57,433
2019-06-30 $55,163
2019-03-31 $34,834
2018-12-31 $34,986
2018-09-30 $33,734
2018-06-30 $32,641
2018-03-31 $33,083
2017-12-31 $33,551
2017-09-30 $33,977
2017-06-30 $33,409
2017-03-31 $32,937
2016-12-31 $33,707
2016-09-30 $33,727
2016-06-30 $32,831
2016-03-31 $31,892
2015-12-31 $31,748
2015-09-30 $31,779
2015-06-30 $31,954
2015-03-31 $33,579
2014-12-31 $33,749
2014-09-30 $33,450
2014-06-30 $33,503
2014-03-31 $33,424
2013-12-31 $38,592
2013-09-30 $36,804
2013-06-30 $36,252
2013-03-31 $35,958
2012-12-31 $35,897
2012-09-30 $36,044
2012-06-30 $31,667
2012-03-31 $32,408
2011-12-31 $32,970
2011-09-30 $32,014
2011-06-30 $31,833
2011-03-31 $30,851
2010-12-31 $31,076
2010-09-30 $31,885
2010-06-30 $31,051
2010-03-31 $30,753
2009-12-31 $31,008
2009-09-30 $30,951
2009-06-30 $29,809
2009-03-31 $29,693
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $171.581B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $71.504B 8.96
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.167B 19.06
Ginkgo Bioworks Holdings (DNA) United States $3.492B 0.00
Myovant Sciences (MYOV) United Kingdom $2.595B 0.00
Arcus Biosciences (RCUS) United States $2.459B 36.91
Biohaven (BHVN) United States $1.112B 0.00
Emergent Biosolutions (EBS) United States $0.588B 4.62
Zymeworks (ZYME) Canada $0.480B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.270B 0.00
Enzo Biochem (ENZ) United States $0.092B 0.00
SQZ Biotechnologies (SQZ) United States $0.042B 0.00
Gelesis Holdings (GLS) United States $0.032B 0.00
Ambrx Biopharma (AMAM) United States $0.020B 0.00